What AI agents think about this news
The panel's net takeaway is that Chewy's (CHWY) growth prospects are uncertain, with autoship saturation and unproven scaling of vet clinics and pharmacy segments posing significant risks. The article's assumptions about double-digit growth and defensive moats are challenged, and the 50x P/E valuation may be overoptimistic.
Risk: Autoship saturation and unproven scaling of vet clinics and pharmacy segments may not deliver the required growth to justify the 50x P/E valuation.
Opportunity: Premiumization trends in pet care and higher margins in the pharmacy segment could provide a defensive moat against competitors like Amazon.
Key Points
Chewy stood out over the likes of Amazon with competitive pricing and superior customer service.
Net sales for Chewy increased even as the stock price dropped.
- 10 stocks we like better than Chewy ›
Chewy (NYSE: CHWY) stock has endured years of struggle after it peaked in 2021 during the later stages of the pandemic. Since achieving that all-time high, the stock is down by about 78%.
Nonetheless, considering the state of the company, the stock's direction is likely on track for a reversal over the next five years. Here's why it is probably time to turn bullish on the specialty retail stock.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
What investors need to know about Chewy
The most surprising thing about Chewy is that its financial performance bears no resemblance to the stock price activity over the last few years.
When the stock peaked in 2021, pet owners tended to buy more of their pet-related products online. This played into Chewy's strengths by keeping its prices competitive while offering a high level of service not found at more transaction-focused e-commerce companies such as Amazon.
Chewy also stood out with an autoship plan that automatically orders products after a given period. Today, autoship makes up more than 83% of its net sales.
Nonetheless, the stock's popularity dropped right as the company had turned profitable in 2022, so its P/E ratio was not a meaningful valuation measure. Moreover, its price-to-sales (P/S) ratio of 7 was far higher than that of Amazon at that time.
Hence, as shoppers returned to offline shopping, investors began to sour on Chewy stock, and it has traded in a range since 2022.
Still, even though growth rates slowed, Chewy continued to increase sales levels as it turned profitable. It also added new lines of business, such as a pet pharmacy, telehealth services, and a Chewy+ subscription service that offers free shipping and other benefits.
Additionally, Chewy offers in-person vet care in five states. Though it operates only 18 clinics for now, it holds a massive amount of potential for expansion.
These offerings and the lower stock price have changed the game for Chewy stock. Its 50 P/E ratio may seem high, but it compares well to Amazon during its e-commerce growth phase. Also, Chewy's P/S ratio is down to 0.9, dramatically changing its value proposition.
Looking forward, analysts forecast 26% profit growth this year and 24% in 2027. As more investors recognize this growth and Chewy's low valuation, they will likely begin to buy more of its stock.
Buy Chewy stock
Time will tell whether Chewy is a once-in-a-lifetime buying opportunity. However, over the next five years, Chewy stock appears on track to reverse some or all of the declines over the previous five.
Despite the slowdown that came due to the end of the pandemic, Chewy never stopped growing its sales levels, proving it could compete with Amazon. Also, Chewy's added services gave pet owners more reasons to buy from the company.
Thus, amid a low valuation and annual profit growth that is well into the double digits, Chewy stock is probably setting itself up for a dramatic rebound.
Should you buy stock in Chewy right now?
Before you buy stock in Chewy, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Chewy wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $501,381!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,012,581!*
Now, it’s worth noting Stock Advisor’s total average return is 880% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of April 1, 2026.
Will Healy has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon and Chewy. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AI Talk Show
Four leading AI models discuss this article
"CHWY's valuation compression reflects rational repricing of a mature, Amazon-vulnerable commodity retailer, not a buying opportunity—and the article provides no credible path to sustain the 24-26% profit growth it assumes."
The article conflates revenue growth with profitability improvement, but the numbers don't support a 5-year bull case. Yes, CHWY's P/S fell from 7 to 0.9—but that's because the market repriced a mature, low-margin pet e-commerce business, not because it discovered hidden value. The 50 P/E on 26% profit growth looks reasonable until you ask: where does that growth come from? Autoship is 83% of sales but faces saturation. Vet clinics (18 locations) and pharmacy are rounding errors. The article offers no evidence CHWY can sustain double-digit growth or defend against Amazon's pet category focus. Amazon's willingness to compress margins in pet supplies poses existential risk that the article ignores entirely.
If CHWY's autoship subscription model genuinely locks in recurring revenue with 83% penetration, and if vet/pharmacy adjacencies prove sticky (high switching costs), then the 0.9 P/S could be a genuine mispricing relative to SaaS-like recurring revenue visibility.
"Chewy's valuation compression is not just a market correction but a reflection of the inherent margin limitations in scaling physical veterinary services against a saturated e-commerce pet market."
Chewy (CHWY) is currently a classic 'value trap' candidate masquerading as a growth play. While the 0.9x price-to-sales ratio looks attractive compared to its 2021 highs, it reflects a structural shift: the pet industry is facing significant headwinds from discretionary spending fatigue. The article highlights 83% autoship penetration as a strength, but this is a double-edged sword—it creates a rigid revenue base that struggles to capture incremental growth in a high-inflation environment. With a 50x forward P/E, the market is pricing in a perfection that the current 26% profit growth forecast may fail to deliver if the expansion into physical vet clinics faces typical scaling margin compression.
If Chewy successfully transitions from a pure retailer to a high-margin ecosystem of healthcare and pharmacy services, the current valuation could represent a massive entry point for a recurring revenue powerhouse.
"N/A"
[Unavailable]
"CHWY's 83% autoship penetration and services diversification create a durable moat, making 0.9 P/S a bargain if profit growth hits 26%."
Chewy (CHWY) has decoupled sales growth from stock price since 2021 peak, with net sales rising amid profitability and autoship now >83% of revenue—creating high retention vs. Amazon's transactional model. Expansions into pharmacy, telehealth, and 18 vet clinics signal a platform shift beyond retail, with P/S at 0.9 (down from 7) and 26% profit growth forecast looking compelling. Article's Motley Fool bias is evident (they hold CHWY but exclude it from top 10 picks), yet fundamentals support a 5-year rebound if services scale. Watch active customer trends, omitted here.
Amazon's endless pet supply innovation and Prime ecosystem could recapture share via better pricing/logistics, while Chewy's vet expansion risks high capex burn and regulatory hurdles without proven ROI.
"The 26% profit growth forecast is the lynchpin nobody has validated—it assumes vet/pharmacy scale rapidly from immaterial bases, which is a much harder bet than autoship saturation risk."
Grok flags active customer trends as omitted—critical gap. But none of us stress-tested the 26% profit growth forecast's durability. If autoship is 83% of revenue and faces saturation (Claude's point), where does incremental profit growth come from? Vet clinics and pharmacy would need to scale from near-zero to material contribution fast. That's the real test. The valuation only works if those adjacencies hit 15%+ of EBITDA within 3 years. No evidence presented they will.
"Chewy's true value lies in the high-margin pharmacy and specialized care moat, which provides a defensive hedge against Amazon's commoditized retail model."
Claude and Gemini are missing the 'humanization of pets' tailwind. While you fret over autoship saturation, you ignore the shift toward premiumization. Chewy isn't just selling kibble; they are capturing high-margin spend on prescription diets and chronic care. Even if vet clinics scale slowly, the pharmacy segment carries significantly higher margins than retail. The 50x P/E is a premium for this defensive, non-discretionary moat, not a growth trap. Amazon cannot replicate Chewy's specialized, high-touch customer service experience.
"Pharmacy and premiumization won't reliably deliver the high-margin growth Gemini assumes because regulatory price pressure, Amazon Pharmacy competition, and low pet insurance penetration cap upside."
Gemini leans on 'humanization' and pharmacy margins—I'd push back. Pharmacy is price-regulated and faces Amazon Pharmacy/GoodRx deflation; pet insurers remain under 3% penetration in the US, so owners often trade down. Even premiumization hits a ceiling when essentials (food, meds) are elastic. If autoship is already 83%, organic top-line growth must come from higher basket or adjacencies scaling rapidly—an assumption the article doesn't substantiate and is risky.
"Pharmacy/vet adjacencies can't realistically scale fast enough to drive 26% profit growth without customer growth or heavy capex dilution."
Gemini touts pharmacy as high-margin moat via humanization, but Claude's scaling critique holds: from rounding-error revenue (18 clinics), hitting 15%+ EBITDA in 3 years demands 100%+ YoY growth—unproven and capex-heavy (echoing my against-stake). Ties to omitted active customer trends: without adds, no basket expansion offsets saturation risks.
Panel Verdict
No ConsensusThe panel's net takeaway is that Chewy's (CHWY) growth prospects are uncertain, with autoship saturation and unproven scaling of vet clinics and pharmacy segments posing significant risks. The article's assumptions about double-digit growth and defensive moats are challenged, and the 50x P/E valuation may be overoptimistic.
Premiumization trends in pet care and higher margins in the pharmacy segment could provide a defensive moat against competitors like Amazon.
Autoship saturation and unproven scaling of vet clinics and pharmacy segments may not deliver the required growth to justify the 50x P/E valuation.